Media store

Media Releases

Basel, 13 January 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has entered into a 15-year, non-exclusive partnership with Illumina to broaden ...

Published on: 23 December 2019

Roche enters licensing agreement with Sarepta Therapeutics to improve the lives of patients living with Duchenne muscular dystrophy

Basel, 23 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Sarepta Therapeutics, Inc. (NASDAQ:SRPT), today announced the signing of a licensing agreement providing Roche exclusive commercial ...

Published on: 19 December 2019

European Commission approves Roche’s Kadcyla for the adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment

Basel, 19 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Kadcyla® (trastuzumab emtansine) for the ...

Upcoming Events

All

30January

Roche Full Year Results for 2019

(GMT)

London, UK

add to calendar

17March

Annual General Meeting (tentative)

(CEST)

Basel, Switzerland

add to calendar

22April

First quarter sales 2020

(CEST)

Basel

23July

Half year results 2020

(CEST)

Basel

Media contacts

For media requests

+41 61 688 8888

Media Relations Team

For all general enquiries

Please call the Roche switchboard on
Phone:+41 61 688 11 11

Media store

Roche and Illumina partner to broaden patient access to genomic testing

Roche enters licensing agreement with Sarepta Therapeutics to improve the lives of patients living with Duchenne muscular dystrophy

European Commission approves Roche’s Kadcyla for the adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment

Roche Full Year Results for 2019

Annual General Meeting (tentative)

First quarter sales 2020

Half year results 2020

Media contacts

For media requests

For all general enquiries